Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV3H6T
|
|||
| Drug Name |
Arabaclofen
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fragile X syndrome [ICD-11: LD55; ICD-10: Q99.2] | Phase 3 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gamma-aminobutyric acid B receptor (GABBR) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| GABAergic synapse | ||||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | Activation of G protein gated Potassium channels | |||
| G alpha (i) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Potassium Channels | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01555333) An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303). U.S. National Institutes of Health. | |||
| REF 2 | Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.